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Mg3Si4Oo(OH)
The use of talc for the production of pleural symphysis was first described by Bethune'5 in 1935. This early work involved the creation of pneumothoraces in cats and dogs followed by the insufflation of iodinated talc. He also described two patients who received a dusting of talc as a preliminary to lobectomy, thus, documenting the first use of intrapleural talc in humans. His observations were confirmed by Singer et al16 and Hanrahan et al17 who simultaneously published studies using talc poudrage and talc slurry in animals.
Several animal models have been used in the study of talc pleurodesis, including cats, dogs, rabbits, pigs, and guinea pigs. Descriptions of gross specimens 3 to 6 weeks after pleurodesis note the presence of macroscopic talc on the parietal surface and occasional filmy adhesions.15-17 Frankel et all8 described dense adhesions in dogs who had undergone talc pleurodesis 3 to 4 months prior to death. In a recent report by Mathlouthi et al,19 dogs given talc by insufflation were examined at 1, 2, 7, 15, and 30 days. Parietal and visceral pleural inflammation at 1 and 2 days was noted. Granulomatous pleural reaction, which was not dose dependent, was also observed.
Early experimental models of talc pleurodesis lacked detailed description of the microscopic process that occurs following the intrapleural application of talc. At 2, 3, 6, 12, and 16 weeks following intrapleural talc (slurry and poudrage), visceral pleural thickening with fibroblast proliferation, macrophage infiltration, and foreign body reaction has been consistently reported in all animal models. Schepers and Durkan20 studied the tissue reaction to intravenously administered and inhaled talc particles; intrapleural administration was not performed. They noted that particle size was more important than particle composition and that tissue reaction was almost negligible when the talc particles were less than 3 Am in size.
To our knowledge, the pleural reaction to talc related to the particle size has not been reported.
Iodine is occasionally included when talc pleurodesis is performed. Singer et al16 noted no difference in the microscopic or macroscopic reaction to talc with or without iodine in rabbits. To our knowledge, there are no clinical or animal studies that compare the pleurodesis potential of talc to talc plus iodine. The efficacy of pleurodesis in those series in which iodine was used is 95 percent (222 of 234), which is similar to the efficacy reported in all other series (90 percent, 1,052 of 1,168). There is one report of an allergic reaction following the use of iodinated talc.2' PREPARATION OF TALC FOR PLEURODESIS Talc used for pleurodesis is United States Pharmacopea (USP) asbestos free and must meet minimal criteria with regard to loss on ignition, acid-soluble substances, water-soluble substances, arsenic, lead, and heavy metals.22 Additional product specifications vary among manufacturers. Talc particle size depends on the nature and quantity of impurities as well as the manufacturing process. Particles are generally less than 50,m in size; fine grades having particles no greater than 10 Am size may be purchased. Talc is available from most suppliers of scientific products and chemicals. Some of the larger suppliers are as follows: (1 While talc is not packaged sterilely by the manufacturer, limitation on the number of micro-organisms is a part of USP specifications and total bacteria count cannot exceed 500/g. Despite the long-term use of talc for pleurodesis, there is no standard method of sterilization. Dry heat sterilization is the most frequently noted method of sterilization. [23] [24] [25] [26] [27] [28] Three different temperatures and durations of sterilization have been reported: 160°C for 2 h,27 1250C for 12 h23 and 132°C for 6 hs.28 Ethylene oxide gas sterilization has also been described,7'9'29 but details have not been published. Most The efficacy of talc in the control of malignant pleural effusions has been compared with several Table 2 . Success was defined differently, primarily on the basis of clinical criteria or radiographic findings. In several studies, the complete and persistent absence of pleural fluid was the determinant of successful pleurodesis, while in others the lack of need for further pleural drainage was the sole criterion. Follow-up times were variable; some patients were followed up long term while others were evaluated for success only at 1 month after pleurodesis. Doses from 1 to 14 g have been used. It is problematic to determine the effect of dose on success since no head-to-head comparisons of similar patient populations have been made. Similar rates of success are noted with .5 g (221 of 241, 91 percent) or >5 g (85 of 97, 88 percent). Using success criteria reported by each author, an overall success rate of 91 percent (657 of 721) was noted. When analyzed by the method of administration, a success rate of 91 percent (151 of 166) was observed after talc slurry and 91 percent (418 of 461) after poudrage.
SAFETY AND LONG-TERM SURVIVAL
Several safety aspects should be considered with intrapleural talc: (1) short-term, procedure-related issues such as pain, fever, infection, systemic embolization, hemodynamic compromise, and respiratory failure; and (2) long-term effects on pulmonary function, survival, and risk of malignancy.
Most pleurodesis agents are associated with pain at the time of instillation into the pleural space. In a review of pleurodesis agents by Walker-Renard and colleagues,55 pain was associated with doxycycline, minocycline, tetracycline, bleomycin, cisplatin, cytarabine, doxorubicin, Corynebacterium parvum, mitomycin C, and talc. The degree of pain associated with talc has been variously reported from nonexistent to severe. Walker-Renard and colleagues55 reported pain with talc in 9 of 131 (7 percent) patients. Both inhalation59'60 and injection60O62 of talc are associated with the development of pulmonary disease. Respiratory insufficiency has been reported with both talc poudrage and talc slurry. Rinaldo and colleaguesc3 reported the development of adult respiratory distress syndrome in three patients who received a 10-g talc slurry via a chest tube; two patients recovered. The mechanism of respiratory failure is unclear; however, the authors speculated that a systemic inflammatory response or talc impurity may have been responsible. Bouchama and associates64 reported a case of acute pneumonitis that followed closed pleural biopsy and 2-g talc slurry pleurodesis; they postulated that respiratory failure occurred from talc emboli to the lungs. Todd and colleagues58 reported respiratory failure/pneumonia in seven patients and Nandi42 reported two deaths secondary to respiratory failure at 3 days and 6 weeks, all in patients who had talc poudrage. In a recent report by Kennedy and colleagues,28 three cases of respiratory failure were attributed to talc slurry pleurodesis. One patient who underwent bilateral, simultaneous talc pleurodesis procedures required mechanical ventilation while two other patients were treated with oxygen and corticosteroids alone. It is doubtful that the method of administration plays a major role in the development of respiratory failure, although the dose of talc may be important.
Death has been reported in several series in which patients underwent talc pleurodesis. Survival data on most patients who receive talc pleurodesis for the treatment of pleural effusion are limited because of the nature of their disease. Mortality has been primarily related to the progression of the underlying disease or in operative procedures involving debilitated patients. Case reports describing the use of talc in nonmalignant effusions support long-term survival without significant sequelae. Long-term follow-up of 240 patients who received talc or kaolin for the treatment of spontaneous pneumothorax70 revealed a higher death rate when compared with a control population. However, the higher death rate was attributed to a selection bias for patients with underlying pulmonary disease and was not attributed to the use of talc. The only other long-term follow-up available66 did not address mortality.
An association between talc and cancer has been described in those who mine and process talc;7' this association is attributed to asbestos, which is commonly found in association with talc. While there is a single report72 of a patient who developed an adenocarcinoma of the pleura 2 years following iodized talc insufflation for spontaneous pneumothorax, talc was not thought to be causative. Lange and colleagues66 noted the absence of mesothelioma 20 to 35 years after talc poudrage. Chappell and associates70 found no increase in lung cancer in another group of patients who were followed up long term. Although no animal studies have been conducted with regard to the carcinogenic potential of intrapleural asbestosfree talc, to our knowledge, there is currently no evidence to suggest that an increase risk of cancer exists in those who undergo talc pleurodesis. 
CONCLUSIONS

